Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

BackgroundAcute respiratory distress syndrome (ARDS) in corona virus disease 19 (COVID-19) is triggered by hyperinflammation, thus providing a rationale for immunosuppressive treatments. The Janus kinase inhibitor Ruxolitinib (Ruxo) has shown efficacy in severe and critical COVID-19. In this study,...

Full description

Bibliographic Details
Main Authors: Sara Völkel, Thomas S. Tarawneh, Laura Sacher, Aditya M. Bhagwat, Ihab Karim, Hildegard I. D. Mack, Thomas Wiesmann, Björn Beutel, Joachim Hoyer, Christian Keller, Harald Renz, Andreas Burchert, Andreas Neubauer, Johannes Graumann, Chrysanthi Skevaki, Elisabeth K. M. Mack
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Medicine
Subjects:
acute respiratory distress syndrome
COVID-19
proteomics
Ruxolitinib
SARS-CoV-2
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1176427/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1176427/full

Similar Items